Oxford-AstraZeneca vaccine shows strong immune response in elderly
- The Oxford-AstraZeneca Covid-19 vaccine candidate shows a strong immune response in adults in their 60s and 70s, according to researchers, raising hopes that it can protect age groups most at risk from the virus.
- Three vaccines - Pfizer-BioNTech, Sputnik and Moderna - have already reported good preliminary data from phase three trials, with one suggesting 94% of people over 65 could be protected from Covid-19.